Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1017–1025. doi: 10.1016/j.ijrobp.2014.12.052

Table 1.

Clinical characteristics (n = 30)

Age (years)
 Median (range) 69 (52 – 87)
Pre-Treatment PSA (ng/mL)
 Median (range) 5.9 (0.9 – 41.0)
Gleason Sum
 5 1 ( 3.3)
 6 8 (26.7)
 7 12 (40.0)
 8 6 (20.0)
 9 3 (10.0)
 10 0 ( 0.0)
NCCN Risk Group
 Low (T1c, PSA <10 ng/mL, Gleason <=6, <50% core positive) 9 (30.0)
 Intermediate (T2b-2c, or PSA 10-20 ng/mL, or Gleason 7) 12 (40.0)
 High (T3a, or PSA > 20 ng/mL, or Gleason 8-10) 9 (30.0)
Anatomic Stage/Prognostic Group (AJCC)
 I 9 (30.0)
 IIA 11 (36.7)
 IIB 10 (33.3)
Prostate Volumes (cm3)
 Median (range) 35.6 (15.8 – 62.8)
Intraprostatic Dominant Lesions (IDL)
 Total Number Defined 31
 IDLSUV60% Volume (cm3)
 Median (range)		 2.7 (0.3 – 10.8)
 IDLSUV70% Volume (cm3)
 Median (range)		 0.7 (0.04 – 7.10)

Values are number (percentage) unless otherwise noted.